Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Assets for 11 consecutive years, with $167.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 23.47% to $167.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $842.1 million, a 4.49% decrease, with the full-year FY2025 number at $167.1 million, down 23.47% from a year prior.
  • Non-Current Assets was $167.1 million for Q4 2025 at Cartesian Therapeutics, down from $225.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $226.2 million in Q3 2024 to a low of $13.6 million in Q1 2021.
  • A 5-year average of $105.7 million and a median of $18.2 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 1299.2% in 2024, then decreased 23.47% in 2025.
  • Cartesian Therapeutics' Non-Current Assets stood at $15.4 million in 2021, then increased by 14.95% to $17.7 million in 2022, then soared by 1107.58% to $214.3 million in 2023, then grew by 1.9% to $218.4 million in 2024, then fell by 23.47% to $167.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Non-Current Assets are $167.1 million (Q4 2025), $225.4 million (Q3 2025), and $225.5 million (Q2 2025).